Skip to search formSkip to main contentSkip to account menu

4SC-202

Known as: HDAC Inhibitor 4SC-202 
An orally bioavailable benzamide and inhibitor of human class I histone deacetylases (HDACs) isoenzymes 1, 2 and 3, with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzamides
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
4SC-202 induces apoptosis in myelodysplastic syndromes and the underlying mechanism.
Epigenetic modifications play crucial roles in regulating the self-renewal and differentiation of hematopoiesis. 4SC-202, a novel… 
2019
2019
LSD1 Inhibitor 4SC-202 Inducing Apoptosis in Myelodysplastic Syndrome Cells Via NF-κb-HO-1 Pathway
Aims: Human histone lysine-specific demethylase 1(LSD1) inhibit gene transcription and thereby block myeloid differentiation… 
2018
2018
Abstract 4722: 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer…
Various histone deacetylases (HDAC) inhibitors were described as beneficially affecting anti-tumoral immune response. Although… 
2017
2017
Abstract 3088: Combination of 4SC-202 and IFN-γ restores mature APC phenotype in AML cells
Acute myeloid leukemia (AML) is characterized by a differentiation block resulting in accumulation of immature myeloid cells… 
2017
2017
Abstract 2632: 4SC-202 induces inflamed tumor microenvironment, strongly enhances tumor infiltration with cytotoxic T cells and primes tumors for anti-PD1/PD-L1 therapy
Various HDAC inhibitors were described as beneficially affecting anti-tumoral immune response. Although different HDAC inhibitors… 
2017
2017
Clinical development of 4SC-202, a combined epigenetic inhibitor of HDAC class I and LSD1, to overcome anti-PD-1 refractoriness and increase efficacy of checkpoint inhibition.
e14096Background: Checkpoint inhibitor (CI) like anti-PD(L)-1 antibodies are a breakthrough innovation, but a high unmet medical… 
2016
2016
4SC-202: Epigenetic modulation to pave the way for checkpoint inhibition.
11546Background: 4SC-202 is an orally available, small molecule clinical stage epigenetic modulator. Epigenetic modifiers are… 
2016
2016
AT-04TOWARDS AN EPIGENETIC THERAPY FOR RHABDOID TUMORS -IN VITRO RESULTS FOR THE EPIGENETIC MODULATORS RESMINOSTAT AND 4SC-202
AT-04. TOWARDS AN EPIGENETIC THERAPY FOR RHABDOID TUMORS -IN VITRO RESULTS FOR THE EPIGENETIC MODULATORS RESMINOSTAT AND 4SC-202… 
2015
2015
V.11 The novel isotype specific HDAC inhibitor 4SC-202 is active in urothelial carcinoma
2010
2010
178 Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)